OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antisense oligonucleotide therapy for KCNT1 encephalopathy
Lisseth Estefania Burbano, Melody Li, Nikola Jancovski, et al.
JCI Insight (2022) Vol. 7, Iss. 23
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Developmental and epileptic encephalopathies
Ingrid E. Scheffer, Sameer M. Zuberi, Heather C. Mefford, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 21

KCNT1-related epilepsies and epileptic encephalopathies: phenotypic and mutational spectrum
Claudia Bonardi, Henrike Heyne, Martina Fiannacca, et al.
Brain (2021) Vol. 144, Iss. 12, pp. 3635-3650
Open Access | Times Cited: 73

Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study
Marina Trivisano, Ilaria Mosca, Licia Salimbene, et al.
Annals of Neurology (2025)
Open Access | Times Cited: 1

The epilepsy–autism phenotype associated with developmental and epileptic encephalopathies: New mechanism‐based therapeutic options
Nicola Specchio, Valentina Di Micco, Eleonora Aronica, et al.
Epilepsia (2025)
Closed Access | Times Cited: 1

RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges
Jong Won Lee, Man Kyu Shim, Hyo‐Suk Kim, et al.
Advanced Drug Delivery Reviews (2023) Vol. 201, pp. 115073-115073
Open Access | Times Cited: 22

Potassium channelopathies associated with epilepsy-related syndromes and directions for therapeutic intervention
Valentin K. Gribkoff, Raymond J. Winquist
Biochemical Pharmacology (2023) Vol. 208, pp. 115413-115413
Closed Access | Times Cited: 20

Efficacy of anti‐seizure medications and alternative therapies (ketogenic diet, CBD, and quinidine) in KCNT1‐related epilepsy: A systematic review
Mathilde Gras, David Bearden, Justin West, et al.
Epilepsia Open (2024) Vol. 9, Iss. 4, pp. 1176-1191
Open Access | Times Cited: 8

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series
Andrew M. Griffin, Kristopher M. Kahlig, Robert J. Hatch, et al.
ACS Medicinal Chemistry Letters (2021) Vol. 12, Iss. 4, pp. 593-602
Open Access | Times Cited: 41

Functional evaluation of epilepsy‐associated KCNT1 variants in multiple cellular systems reveals a predominant gain of function impact on channel properties
Christopher A. Hinckley, Zhonghua Zhu, J Chu, et al.
Epilepsia (2023) Vol. 64, Iss. 8, pp. 2126-2136
Closed Access | Times Cited: 16

A Natural History ofNAA15-related Neurodevelopmental Disorder Through Adolescence
Rikhil Makwana, Carolina Christ, Rahi Patel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6

Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases
Harry Wilton-Clark, Eric Yan, Toshifumi Yokota
Genes (2024) Vol. 15, Iss. 7, pp. 821-821
Open Access | Times Cited: 6

Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies
Paloma García Quilón, Greta Volpedo, Serena Cappato, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 11
Open Access | Times Cited: 6

KCNT2Related Disorders: Phenotypes, Functional, and Pharmacological Properties
Maria Cristina Cioclu, Ilaria Mosca, Paolo Ambrosino, et al.
Annals of Neurology (2023) Vol. 94, Iss. 2, pp. 332-349
Open Access | Times Cited: 13

Are Genetic Therapies for Epilepsy Ready for the Clinic?
James S. Street, Yichen Qiu, Gabriele Lignani
Epiliepsy currents/Epilepsy currents (2023) Vol. 23, Iss. 4, pp. 245-250
Open Access | Times Cited: 13

Recent advances and current status of gene therapy for epilepsy
Aojie Cai, Kai Gao, Fan Zhang, et al.
World Journal of Pediatrics (2024) Vol. 20, Iss. 11, pp. 1115-1137
Closed Access | Times Cited: 4

Haploinsufficiency, Dominant Negative, and Gain-of-Function Mechanisms in Epilepsy: Matching Therapeutic Approach to the Pathophysiology
Gemma L. Carvill, Tyler Matheny, Jay R. Hesselberth, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 3, pp. 1500-1514
Open Access | Times Cited: 27

Natural History of NAA15‐Related Neurodevelopmental Disorder Through Adolescence
Rikhil Makwana, Carolina Christ, Rahi Patel, et al.
American Journal of Medical Genetics Part A (2025)
Open Access

Functional verification and allele-specific silencing of a novel AKT3 variant that causes megalencephaly, polymicrogyria and intractable epilepsy
Yosuke Miyamoto, Takenori Tozawa, Eisuke Ichise, et al.
Journal of Human Genetics (2025)
Closed Access

Merritt-Putnam Symposium | Developmental and Epileptic Encephalopathies—Current Concepts and Novel Approaches
Rod C. Scott, Jenny Hsieh, Amy McTague, et al.
Epiliepsy currents/Epilepsy currents (2025)
Open Access

Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies
Debopam Samanta, Sonal Bhatia, Senyene E. Hunter, et al.
Pediatric Neurology (2025) Vol. 168, pp. 67-81
Closed Access

The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing
Jillian Belgrad, Erin M. McConnell, Simon Léonard, et al.
Nucleic Acids Research (2025) Vol. 53, Iss. 8
Open Access

Overgrowth-intellectual disability disorders: progress in biology, patient advocacy and innovative therapies
Cooper Atterton, Isabella Trew, Jessica M. Cale, et al.
Disease Models & Mechanisms (2025) Vol. 18, Iss. 5
Open Access

Page 1 - Next Page

Scroll to top